<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751295</url>
  </required_header>
  <id_info>
    <org_study_id>2012-08-052</org_study_id>
    <nct_id>NCT01751295</nct_id>
  </id_info>
  <brief_title>Statin and Post-interventional Coronary Microcirculation Dysfunction</brief_title>
  <official_title>Effect of Statin on the Post-interventional Coronary Microcirculation Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of statin on the coronary&#xD;
      microcirculation dysfunction measured after percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Development of peri-procedural myocardial infarction following percutaneous coronary&#xD;
      intervention (PCI) is not uncommon and affects long-term prognosis. Clinical studies have&#xD;
      shown that pre-treatment with atorvastatin reduced peri-procedural myocardial infarction in&#xD;
      patients with stable angina. The mechanism of peri-procedural myocardial infarction is&#xD;
      presumed to be microvascular embolization. However the direct causal relationship between&#xD;
      statin pretreatment and prevention of microvascular dysfunction has not been investigated&#xD;
      yet.&#xD;
&#xD;
      In this study, we will recruit symptomatic angina patients who have clinical indication of&#xD;
      coronary angiography. At the time of enrollment, patients will be randomly assigned to&#xD;
      pre-treatment group (atorvastatin 80 mg/d for 4 days) or control group. Percutaneous coronary&#xD;
      intervention (PCI) will be perfomed based on the result of diagnostic coronary angiography by&#xD;
      decision of attending physician. When PCI is performed, fractional flow reserve (FFR) and&#xD;
      index of microvascular resistance (IMR) will be measured before and after the procedure.&#xD;
      Periprocedural myocardial infarction will be defined by post-PCI cardiac biomarker. All&#xD;
      patients will be followed for adverse cardiac events for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-procedural IMR of PCI target vessel Post-procedural IMR of PCI target vessel</measure>
    <time_frame>within 1 year after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-procedural troponin I</measure>
    <time_frame>within 1 year after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedural FFR</measure>
    <time_frame>within 1 year after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedural IMR comparison of target vessel with non-target vessel</measure>
    <time_frame>within 1 year after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI with atorvastatin pre-treatment group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>PCI without atorvastatin pre-treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI</intervention_name>
    <arm_group_label>atorvastatin</arm_group_label>
    <other_name>lipinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A. Finished informed consent&#xD;
&#xD;
          -  B. Stable angina with clinical indication of coronary angiography&#xD;
&#xD;
          -  C. Age ≥ 21 year and ≤ 80 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A.Without informed consent&#xD;
&#xD;
          -  B.PCI target lesion is not adequate or not indicated for FFR/IMR study&#xD;
&#xD;
          -  C.Prior myocardial infarction or interventional procedure for PCI target vessel&#xD;
&#xD;
          -  D.Myocardial infarction within 30 days&#xD;
&#xD;
          -  E.Usage of statin, current or within 1 month&#xD;
&#xD;
          -  F.Prior bypass surgery&#xD;
&#xD;
          -  G.Impaired renal function (Creatinine &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  H.Impaired left ventricular function (ejection fraction &lt; 40%)&#xD;
&#xD;
          -  I.Active hepatitis or abnormal hepatic transaminase level (&gt; 3 ULN)&#xD;
&#xD;
          -  J.Contraindication for long-term antiplatelet agent or statin&#xD;
&#xD;
          -  K.Planning or potential of pregnancy&#xD;
&#xD;
          -  L.Neoplastic disease without evidence of treatment completion&#xD;
&#xD;
          -  M.Impaired general condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gang nam-Gu, Ilwon-Dong</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jin-Ho Choi</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

